Maravai Lifesciences Holdings Inc

1. 1

   Election of Directors

   ManagementBoard: FOR

   Elect three nominees—Bernd Brust, Gregory T. Lucier, and Luke Marker—to the Board to serve three-year terms expiring in 2029.

2. 2

   Ratification of Appointment of Independent Registered Public Accounting Firm

   ManagementBoard: FOR

   Ratify the appointment of Deloitte & Touche LLP as Maravai’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

3. 3

   Advisory Vote on the Compensation of Our Named Executive Officers (Say-on-Pay

   ManagementBoard: FOR

   A non-binding, advisory vote to approve the compensation of the Company’s named executive officers as disclosed in the proxy statement.

   More detail

   This management proposal asks shareholders to cast a non-binding advisory vote approving the Company’s disclosed compensation for its named executive officers (NEOs). Management seeks this approval primarily to confirm investor support for its executive pay program and to respond to regulatory and governance expectations that companies solicit shareholder feedback on compensation. The Compensation and Leadership Development Committee has emphasized a pay-for-performance philosophy: a significant portion of NEO pay is at-risk and equity-based, long-term incentive awards (including PSUs tied to stock-price hurdles) are used to align management outcomes with shareholder value, and the Committee engaged an independent consultant to benchmark and redesign awards. The proposal comes in the context of significant leadership transitions in 2025 (a new CEO and CFO) that required guaranteed pro‑rated bonuses for new hires, mid-year adjustments to the 2025 annual incentive plan, reduced 2025 equity grant values versus 2024, and longer RSU vesting to address investor concerns about short vesting schedules. Management also adjusted the peer group and in 2026 plans to shift long-term incentive vesting to EBITDA performance to better link pay to operating performance. The Board recommends a FOR vote, arguing that the program balances retention during transition, cost discipline, and alignment with long-term shareholder interests. While the vote is non-binding, a negative outcome would prompt the Board and Compensation Committee to reassess program design and investor engagement; historically the Company received 80.9% support on say-on-pay in 2025, signaling substantial institutional backing but also room for improvement. Investors evaluating the proposal should weigh the trade-offs between near-term retention needs created by leadership changes and the Committee’s efforts to strengthen long-term alignment through performance-based equity and governance-responsive design changes.

Upcoming shareholder meetings at Maravai Lifesciences Holdings Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.

When is the Maravai Lifesciences Holdings Inc 2026 annual meeting?

Maravai Lifesciences Holdings Inc (MRVI) holds its 2026 annual shareholder meeting on Tuesday, May 26, 2026.

What is the record date for the Maravai Lifesciences Holdings Inc 2026 meeting?

The record date for the Maravai Lifesciences Holdings Inc 2026 meeting is Friday, March 27, 2026. Shareholders of record on or before that date are eligible to vote.

Who are the director nominees for Maravai Lifesciences Holdings Inc's 2026 meeting?

The board is presenting 3 director nominees at the Maravai Lifesciences Holdings Inc 2026 meeting, listed with their independence status and background.

What proposals will shareholders vote on at the Maravai Lifesciences Holdings Inc 2026 meeting?

Shareholders will vote on 3 proposals at the Maravai Lifesciences Holdings Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.